contraindications: Androgen-dependent tumours (prostate or breast carcinoma) — absolute contraindication
Hypersensitivity to testosterone enanthate or sesame/benzyl-based carrier oils
Polycythaemia vera or untreated secondary erythrocytosis
Severe hepatic impairment or active hepatic pathology
Not approved for use in women of reproductive potential due to virilisation risk
side_effects: Erythrocytosis: elevated RBC mass and haematocrit — monitored by full blood count
Aromatisation to oestradiol — gynecomastia and fluid retention if unmanaged; managed with aromatase inhibitors
Endogenous testosterone suppression via HPTA negative feedback — expected and managed through PCT
Androgenic effects: seborrhoea, accelerated androgenic alopecia in genetically predisposed individuals
Lipid profile shifts — LDL/HDL ratio changes documented in pharmacological studies at supraphysiological doses
Injection-site reactions: transient local soreness or erythema, minimised by site rotation
monitoring: Serum total and free testosterone, oestradiol (LC-MS/MS preferred), LH, FSH — baseline then every 6–8 weeks
Full blood count including haematocrit and haemoglobin — haematocrit above 52% requires dose review
Full lipid panel (LDL, HDL, triglycerides) at baseline and at cycle mid-point
Blood pressure — supraphysiological androgen exposure can elevate systolic readings
PSA (prostate-specific antigen) for users over 35 — annual baseline recommended
pct: Initiate PCT approximately 14–16 days after the final Pharm-Tec Testosterone Enanthate injection to allow ester clearance
Standard professional PCT: clomiphene citrate 50mg/day or tamoxifen 20mg/day for 4–6 weeks, duration scaled to cycle length
HCG administered during the final weeks of the cycle (not after) helps preserve Leydig-cell responsiveness ahead of PCT
Bloodwork including LH, FSH, and total testosterone at PCT conclusion confirms HPTA recovery status